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1. Introduction 
Articular cartilage tissue is mostly composed of extracellular matrix (ECM) in which a 
sparse population of cells (chondrocytes) reside. These cells produce both anabolic and 
catabolic factors that perpetuate a homeostatic process of ECM breakdown and repair 
termed cartilage turnover. This balance between tissue anabolism and catabolism is 
characteristic of normal articular cartilage. However, during osteoarthritis (OA), this process 
is disrupted due to disregulation of chondrocyte function. Although articular cartilage is 
anatomically classified as a single tissue type, it is divided into four zones defined by their 
physiological position relative to the joint surface. Likewise, the populations of 
chondrocytes housed within these zones and their respective ECMs often differ from one 
another in both appearance and organization.  The calcified zone lies directly on top of the 
subchondral bone, which the cartilage tissue shields from physical forces. This zone contains 
a very small population of chondrocytes that are slowly being replaced by bone forming 
cells (osteoblasts) continuously throughout life. When compared to other cartilage zones, the 
calcified zone ECM is highly mineralized and contains the sparsest chondrocyte population. 
Osteoblasts from the neighboring subchondral bone secrete bone morphogenic factor 
(BMPs), and other factors such as stromal cell derived factor 1 (SDF-1) which promote 
chondrocyte hypertrophy and mineralization.  The deep zone cartilage layer lies directly 
above the calcified zone and contains small vertical aggregates of chondrocytes embedded 
within a uniquely organized ECM which histologically resemble columnar structures. The 
middle zone is by far the largest layer containing round bodied chondrocytes and a well 
hydrated and robust collagen ECM network. Chondrocyte content increases gradually from 
the subchondral bone towards the articular surface that is in direct contact with the joint 
synovium. The superficial zone (A.K.A. tangential zone) makes up the articular surface and 
therefore contains the largest number of chondrocytes of all four zones. OA can affect just 
one or all four of these cartilage zones depending on the severity and pathological stage of 
the disease. Given its anatomical position, the superficial zone is often the first cartilage 
tissue zone to be exposed to injury or wear-and–tear due to excessive joint loading. 
Therefore this zone often appears to be the initial point of OA pathogenesis. During early 
stage OA, a sustained injury to the articular surface initially induces a mild but chronic 
inflammatory response (Martel-Pelletier et al., 2008) that slowly manifests into the 
disruption of cartilage homeostasis due to disredulation of chondrocyte function (Goldring 
& Marcu, 2009). As the disease persists, continued homeostatic imbalances eventually cause 
the release of excessive amounts of catabolic enzymes that break down the ECM resulting in  
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lesion formation within the articular cartilage tissue. Similarly, the disregulated release of 
anabolic factors such as BMPs and IHH by chondrocytes can result in chondrocyte 
hypertrophy and eventually calcification of the cartilage ECM.  Such changes often lead to 
osteophyte (bone spur) formation on the otherwise smooth articular surface making normal 
movement painful and destructive to the connective tissue demonstrating the importance of 
ECM microenvironment to cartilage tissue health.  
2. Structure and function of cartilage ECM molecules and their mutations in 
degenerative joint diseases 
Articular cartilage is an avascular aneural connective tissue composed of chondrocytes that 
produce and maintain a robust ECM protein network. During early bone development, 
mesenchymal stem cells of the chondrogenic progeny undergo differentiation into 
chondrocytes which proliferate, mature, and eventually calcify and undergo cell death as 
they are replaced by bone. This process leaves behind a layer of articullar cartilage that 
covers the surfaces of bones providing a low friction surface that can act as a weight/shear 
stress-bearing coat allowing for smooth joint transition during movement. Articular 
cartilage tissue has high water content contributing to its near frictionless nature.  
2.1 Collagens   
Articular cartilage ECM is composed mainly of three kinds of macromolecules: (1) collagens, 
(2) proteoglycans and (3) non-collagenous matrix proteins. Several collagens are cartilage 
specific including type II, VI, IX, X, and XI. Table 1 lists the most common cartilage ECM 
proteins and human diseases that result from their mutation, including their association 
with chondrodysplasia and OA. 
2.1.1 Collagen II 
Type II collagen makes up approximately 80 to 90 percent of all collagen content found in 
normal healthy articular cartilage tissue. In OA, tissue degradation is predominantly caused 
by the breakdown of cartilage ECM due to the overabundance of reactive proteases, many 
of which cleave type II collagen containing fibrils resulting in tissue destabilization due to 
reduction in tensile strength.  Type II collagen is initially synthesized as pro-alpha-chains 
that are assembled into a triple helical structure by the globular domains that exist at both 
its N and C terminal ends. Two forms of pro-collagen are found in cartilage: Type IIA 
(COL2A1) and Type IIB. These trimeric type II collagen molecules crosslink with other 
collagens (i.e. type IX and XI) to form large fibrils that compose a web-like network, which 
binds to various ECM molecules. The stability of the triple helical structure provides the 
strength required by cartilage to resist tensile stress and also prevents type II collagen from 
being easily degraded by most endogenous proteases found in the tissue. Due to its long 
half-life (over 100 years under physiological conditions) and relative stability, the type II 
collagen network is never completely broken down or remodeled during normal cartilage 
homeostatic processes. Type II collagen mutations can cause a plethora of mild to severe 
phenotypes depending on the nature and location of the mutation. While heterozygous 
deletion of this gene in mice show a minimal phenotype, complete homozygous deletion 
predictably causes severe cartilage tissue disorganization and death shortly after birth (Li et 
al., 1995). In addition to being linked to the development of degenerative joint diseases such  
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Protein Gene(s) 
Human diseases  
caused by mutations 
Chondrodysplasia
OA 
causative 
Type II 
collagen 
COL2A1 
Stickler syndrome Yes (mild) May 
Achondrogenesis (type II) Yes 
No 
evidence 
Hypochondrogenesis Yes 
No 
evidence 
Spondyloepiphyseal 
dysplasia 
Yes May 
Spondyloepimetaphyseal 
dysplasia 
Yes May 
Type VI 
collagen 
COL6A1, 
COL6A2, 
COL6A3 
Ullrich congenital muscular 
dystrophy 
No evidence 
No 
evidence 
Bethlem myopathy No evidence 
No 
evidence 
Type IX 
collagen 
COL9A1, 
COL9A2, 
COL9A3 
Multiple epiphyseal 
dysplasia 
Yes May 
Lumbar disk disease No evidence 
No 
evidence 
Premature OA No evidence Yes 
Type X 
collagen 
COL10A1 
Schmid metaphyseal 
dysplasia 
Yes 
No 
evidence 
Spondylometaphyseal 
dysplasia 
Yes May 
Type XI 
collagen 
COL11A1, 
COL11A2 
Stickler syndrome Yes (mild) May 
Spondylomegaepiphyseal 
dysplasia 
Yes May 
Premature OA No evidence Yes 
Aggrecan ACAN Several chondrodysplasias Yes May 
Matrilin-3 MATN3 
Multiple epiphyseal 
dysplasia 
Yes May 
Spondyloepimetaphyseal 
dysplasia 
Yes May 
Premature OA No evidence Yes 
Cartilage 
oligomeric 
matrix 
protein 
COMP 
Pseudoachondroplasia Yes May 
Multiple epiphyseal 
dysplasia 
Yes May 
Lubricin PRG4 
Camptodactyly-
arthropathy-coxa vara-
pericarditis syndrome 
No evidence 
No 
evidence 
Table 1. Cartilage matrix proteins and common human diseases associated with their 
mutation, including their association with chondrodysplasia and osteoarthritis (OA)  
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as familial OA, various mutations in this molecule can cause more severe phenotypes such 
as Stickler syndrome, and several major chondrogenic defects (Byers, 2001). A mutation in 
the alpha helical domain causing a substitution of a glycine codon with a larger amino acid 
has been shown to disrupt proper alpha helix formation of type II collagen leading to severe 
chondrodysplasias and a significant reduction in cartilage tissue stability (Kuivaniemi et al., 
1997; Prockop et al., 1997). Similarly in the 1990s, particular families were discovered to have 
missense mutation (R519C) causing the production of abnormal type II collagen pro-alpha-
chains. These alpha chains formed protein dimers leading to mild chondrodysplasia 
followed by a unique form of familial OA (Byers, 2001; Eyre et al., 1991; Pun et al., 1994; 
Bleasel et al., 1998).  
2.1.2 Collagen XI 
Type XI collagen is the second most abundant collagen (3% of all collagens) found in adult 
articular cartilage and it is a core component of collagen fibrils. It is a heterotrimeric 
molecule composed of three alpha-chains. Interestingly, the first two chains are coded by the 
COL11A1 and COL11A2 genes respectively while the third chain is coded by COL2A1 and 
uniquely post transcriptionally modified (Martel-Pelletier et al., 2008). Type XI collagen 
makes hydroxylysine-based aldehyde cross-links with type II collagen to form collagen 
fibrils that stabilize articular cartilage (Cremer et al., 1988) and it has been suggested that the 
ratio of type XI to type II determines collagen fibril diameter and tensile strength. Like 
COL2A1, mutations in the type XI collagen genes can cause Stickler syndrome. A study 
done in 1995 also discovered that a single base pair deletion in the type XI collagen gene 
creates a frame shift resulting in a premature stop codon which is functionally equivalent to 
knocking out the gene itself (Li et al., 1995). Mice that are homozygous for this nonsense 
mutation develop serious chondrodysplasia and die at birth. Missense mutations in the 
COL11A2 gene have also been associated with spondylo-megaepiphyseal dysplasia 
(OSMED) (Vikkula et al., 1995) and mutations in both COL11A1 and COL11A2 can cause 
premature development of OA (Rodriguez et al., 2004). 
2.1.3 Collagen IX 
Type IX collagen is normally co expressed with type II collagen in hyaline cartilage. In 
adults, this collagen makes up about 1% of the collagen content found in the articular 
cartilage. Similar to type VI collagen, type IX collagen molecules exist in heterotrimeric form 
composed of three alpha-chains. Each of these heterotrimers has seven sites with which to 
form cross-links with other collagen molecules. Type IX collagen is found to be covalently 
bonded through aldimine-derived crosslinks to the surface of large type II collagen fibrils 
(Wu et al., 1992) and it is believed to constrain the lateral expansion of these fibrils (Blaschke 
et al., 2000; Gregory et al., 2000). Missense mutations in the type IX collagen genes have been 
associated with lumbar disk disease (LDD) (Zhu et al., 2011) and multiple epiphyseal 
dysplasia (MED) (Jackson et al., 2010) which indirectly leads to the development of OA.  
Surprisingly, mice deficient in type IX collagen exhibit normal signs of skeletal and chondral 
development; however they are afflicted by early joint cartilage degradation that resemble 
the formation of OA-like lesions (Hu et al., 2006).  
2.1.4 Collagen VI 
Hyaline cartilage contains a relatively low content of type VI collagen (less than 2% of all 
articular cartilage tissue collagens) that is found in all cartilage zones within the pericellular 
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regions around chondrocytes (Pullig et al., 1999). Type VI collagen molecules are of 
heterotrimeric organization as they are composed of three non-identical alpha chains.  Each 
chain contains a triple helical domain allowing for the formation of dimers and tetramers 
with each other (Engel et al., 1985; Furthmayr et al., 1983). Type VI collagen interacts with 
non-collagenous matrix proteins forming a network in the pericellular regions. It has been 
previously demonstrated that type VI collagen content is increased in certain patients 
suffering from OA. However, it is suspected that disregulated tissue homeostasis causes 
excessive collagen anabolism and deposition (Pullig et al., 1999). Mutations in the genes that 
code for the three type VI collagen alpha chains have been associated with noncartilage-
specific abnormalities such as muscular dystrophy (Pace et al., 2008) and Bethlem myopathy 
(Lamandé et al., 1998). And a study conducted in 2009 demonstrated that COL6A1 
homozygous knockout mice display lower bone mineral density and develop OA more 
rapidly than wild-type mice of the same genetic background (Alexopoulos et al., 2009).  
2.1.5 Collagen X 
Chondrocytes only express type X collagen within the hypertrophic zone of the growth 
plate (Linsenmayer et al., 1988). It is a homotrimer composed of three pro-alpha-chains each 
containing a C terminal alpha helical domain which allows these chains to assemble into 
short triple helixes (Wagner et al., 2000). It has been demonstrated that type X collagen 
expression and distribution is altered during OA such that these molecules are found among 
the noncalcified regions of the articular cartilage implying the occurrence of premature 
chondrocyte hypertrophy in these zones (von der Mark et al., 1992). Abnormalities in type X 
collagen can cause spinal and metaphyseal dysplasias (i.e. Schmid MCD) due to improper 
enchondral ossification (Bignami et al., 1992). A heterozygous missence mutation 
(Gly595Glu) in the COL10A1 gene was also previously found to correlate with 
spondylometaphyseal dysplasia (SMD) within a certain family (Ikegawa et al., 1998). And 
transgenic mice with deletions in the triple-helical domain of type X collagen develop SMD 
(Jacenko et al., 1993). 
2.2 Proteoglycans 
The second major structural components of articullar cartilage tissue are proteoglycans of 
which aggrecan is the most common. These ECM proteins predominantly help cartilage 
tissue to retain water and withstand compressive force during joint transition and loading.  
2.2.1 Aggrecan 
Aggrecan is a large chondroitin sulfate proteoglycan that consists of a 220 kDa protein core 
containing three globular domains (G1, G2 and G3) which allow it to form covalent bonds 
with its glycosaminoglycan (GAG) side chain components (Doege et al., 1991).  Each GAG 
side chain is composed of a single keratin sulfate and two chondroitin sulfate domain 
regions all of which are adjacent to the G2 and G3 globular domains. The G1 domain is 
attached to a link protein that enables multiple aggrecan subunits to bind to a long 
nonsulfated glycosaminoglycan backbone known as hyluronic acid (HA). Thus aggrecan 
becomes trapped within the collagen network where some suspect that it acts to physically 
shield type II collagen from proteolytic cleavage (Pratta et al., 2003). Due to its overall 
negative charge, aggrecan draws water into the cartilage ECM allowing the tissue to swell. 
This swelling gives the tissue a spring-like quality helping it to withstand compressive 
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forces that are applied to the joint during movement. Proteolytic cleavage of this vital ECM 
protein is mediated by proteases known as aggrecanases. During OA, the disregulation of 
aggrecanase synthesis and release causes much damage to aggrecan molecules and the 
cartilage tissue loses the ability to retain water as it suffers from a reduction in overall 
stability. As is the case with type II collagen and other major cartilage ECM proteins, 
deletions/mutations in aggrecan lead to severe chondrodysplasia which can often cause 
premature OA.   
2.2.2 Hyaluronic acid 
HA is a nonsulfated GAG that is covalently linked to aggrecan monomers and allows these 
subunits to aggregate in the cartilage ECM. HA species can have varying molecular mass 
depending on the length of the GAG. Their masses can range from as small as fifty to larger 
than thousands of Kilodaltons. The molecular weight of HA decreases during normal aging 
due to proteolytic cleavage and the cartilage tissue of young individuals tends to have larger 
species of HA compared to that of the elderly. In addition to the cartilage ECM, HA is also 
largely found in synovial fluid and contributes to its viscoelasticity.  HA recognizes and 
specifically binds several different cell surface receptors (i.e. CD44, ICAM-1 and RHAMM) 
where it remains as a major component of the pericellular network surrounding 
chondrocytes. Due to its large size, HA can shield cells from coming into contact with 
inflammatory mediators such as cytokines and chemokines. It has also been suggested that 
HA can regulate collagenase and aggrecanase expression from chondrocytes and synovial 
cells. Previous studies have demonstrated that higher molecular mass species of HA can 
inhibit IL-1 mediated stimulation of certain MMPs and ADAMTS-4 by interacting with 
CD44 (Julovi et al., 2004; Wang et al., 2006; Theuns et al., 2008) while the opposite effect has 
been found to occur in the presence of smaller mass species (20 kDa) of this proteoglycan. 
Additionally, these larger species can also inhibit proteoglycan release from cartilage tissue 
ECM. HA is currently used as an intra-articularly therapy via joint injection for knee OA as 
this long proteoglycan is believed to decrease OA associated joint pain by increasing both 
the viscoelastic properties of synovial fluid and the lubrication of the articular surface 
preventing tissue tearing due to the friction generated during joint transition. (Moreland, 
2003; Wobig et al., 1998; Altman & Moskowitz, 1998). Its efficacy in relieving OA related 
pain has been reported to be depend on the molecular mass of the HA chains as species of 
larger molecular mass were found to have a greater effect in reducing joint pain. Although 
the exact biological mechanism with which HA relieves OA associated joint pain remains to 
be elucidated, it is believed that this large proteoglycan supplements the natural synovial 
fluid increasing its viscoelasticity and reducing the friction generated during joint 
movement.    
2.2.3 Leucine-rich small proteoglycans 
Articullar cartilage also consists of a group of small proteoglycans classified for having 
seven to eleven leucine-rich repeats (SLRPs). The major cartilage SLRPs are decorin, 
biglycan, fibromodulin, lumican and epiphycan in the order of decreasing abundance. These 
small proteoglycans have several roles in maintaining cartilage tissue ECM organization and 
homeostasis such as interacting with various collagen species to strengthen the ECM 
network and protecting collagen fibrils from proteolytic cleavage by collagenases. The 
SLRPs decorin and biglycan are similar in structure as both consist of a leucine-rich core 
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protein linked to either one (in the case of decorin) or two (in the case of biglycan) 
chondroitin/dermatan sulfate containing GAG chain(s). Previous literature has suggested 
that decorin can alter the cell cycle by modulating growth factor (i.e. TGF-ǃ and EGF) 
signaling and it is currently studied in cancer research. Although similar in structure to 
decorin, biglycan has a different physiological role in ECM. It has been suggested that this 
proteoglycan modulates BMP-4 signaling during osteoblast differentiation (Chen et al., 
2004). Biglycan is essential during skeletal development to maintain normal bone mineral 
density. Fibromodulin and lumican are SLRPs that competitively bind the same region of 
collagen fibrils helping to regulate fibril diameter and ECM network assembly (Svensson et 
al. 2000). Epiphycan is a dermatan sulfate proteoglycan with seven leucine-rich repeats 
believed to maintain joint integrity, yet little is known about its function and the biological 
mechanism with which it protects tissue.  Mutations and/or deletions in SLRP genes are 
associated primarily with connective tissue and eye disorders. One recent study 
demonstrated that biglycan and epiphycan double knockout mice are normal at birth but 
develop several skeletal abnormalities later in life along with premature OA (Nuka et al., 
2010).   But there have yet to be more studies that suggest abnormalities in these genes are 
linked to degenerative joint diseases. Given the importance of SLRPs in regulating tissue 
homeostasis and matrix organization, this is quite surprising.     
2.3 Non-collagenous matrix proteins 
Other important non-collagenous matrix proteins found in articular cartilage include the 
matrilins (matrilin-1 and -3), the cartilage oligomeric matrix protein (COMP), and the 
lubricating protein predominantly secreted by chondrocytes of the superficial zone: 
lubricin.   
2.3.1 Matrilins 
The matrilins are a family of noncollagenous oligomeric ECM proteins that are found in a 
broad range of tissues including articular cartilage and bone (Deak et al., 1999; Wagener et 
al., 1997; Piecha et al., 1999; Klatt et al., 2001). There are currently four known members 
within this family. MATN1 and MATN3 are cartilage specific while MATN2 and MATN4 
are found in many connective tissue types (van der Weyden et al. 2006; Wu et al., 1998; 
Piecha et al., 2002). It has been demonstrated that matrilins form a filamentous network 
pericellularly in the cartilage ECM (Klatt et al., 2000). Structurally, MATN1 consists of two 
Von Willebrand Factor A (vWFA) domains, one epidermal growth factor-like (EGF) domain, 
so named because they share a forty amino-acid long residue commonly found in epidermal 
growth factor protein, and one alpha helical coil-coiled oligomerization domain. Each vWFA 
domain contains a metal ion-dependant adhesion site (MIDAS) and previous studies have 
demonstrated that its mutation can abolish filamentous network formation resulting in 
abnormal ECM assembly (Chen  et al., 1999).  Its coil-coiled oligomerization domain allows 
it to form homotrimers with other MATN1 molecules or hetero-oligomers with MATN3. 
MATN1 is expressed by post proliferative chondrocytes that constitute the zone of 
maturation within the growth plate. MATN1 interacts with both type II collagen and 
aggrecan playing a role in organizing fibril formation. MATN1 knockout mice exhibit 
abnormal fibrillogenesis as their collagen fibrils become aggregated in a uniform directional 
orientation as opposed to the normal matrix network-like organization observed in wild-
type animals.  
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Although mutations of MATN1 have not been associated with the development of 
degenerative joint diseases, MATN3 is the smallest and most recently discovered member of 
the matrilin family of ECM proteins. MATN3 contains a single vWFA domain, four EGF-like 
domains, and one alpha-helical oligomerization domain which allows it to form homo-
oligomers with other MATN3 peptides and hetero-oligomers with MATN1 (Klatt et al., 
2000). MATN3 is naturally found in the articular cartilage in its tetrameric form composed 
of four single oligomers covalently bound together by their alpha-helical oligomerization 
domains. Several known MATN3 mutations can lead to developmental abnormalities in 
articular cartilage and bone. These mutations can eventually either lead to OA directly, in 
the case of hand OA (Aeschlimann et al., 1993; Cepko et al., 1992) or indirectly, in the case of 
MED, which manifests with joint pain and early onset OA (Chen et al., 1992; Chen et al., 
1993).  A threonine to methionine missense mutation (T298M) in the first EGF-like domain 
of MATN3 has been found to correlate with the development of hand OA (Stefánsson et al., 
2003) while a cystine to serine (C299S) missense mutation in this same region is common to 
many patients suffering from spondylo-epi-metaphyseal dysplasia (SEMD), which is a 
condition often leading to vertebral, epiphyseal/metaphyseal anomalies during 
development (Borochowitz et al., 2004). Likewise, an arginine to tryptophan missense 
mutation (R116W) in the vWFA domain has been associated with MED. It was discovered 
that this particular mutation prevents normal secretion of MATN3 from chondrocytes due 
to a dominant negative interaction between mutant and normal MATN3 quickly leading to 
an increase in MATN3 retention within the endoplasmic reticulum of these cells (Otten et 
al., 2005). Consequently, this reduction in the secretion of functional MATN3 is believed to 
contribute to MED. Interestingly, during advanced stages of OA, joint synovial fluid 
contains higher levels of cleaved ECM proteins including MATN3 oligomers due to the 
proteolysis of articular cartilage. One study has even shown that MATN3 mRNA is 
upregulated in some OA patients suggesting that the body may produce an excess of the 
protein (Pullig et al., 2002). Matrilin proteins are relatively well conserved between mice and 
humans making them ideal proteins to investigate in the mouse model. Complete 
homozygous deletion of the MATN3 gene in mice surprisingly results in no gross skeletal 
deformities at birth, but it does however result in the development of OA much earlier in 
life. MATN3 knockout mice were maintained in a C57BL/6J background and developed 
several signs of enhanced OA including osteophyte formation and the presence of large 
lesions in the superficial zone of the articular cartilage, which is the layer that is in direct 
contact with the knee joint synovium. Additionally, these knockout mice appear to have a 
higher bone mineral density (BMD) and lower overall cartilage proteoglycan content when 
compared to wild-type mice of the same genetic background. Perhaps the increase in BMD 
leads to over-loading of diarthroidial joints,  which eventually manifests in the form of 
enhanced cartilage damage. Tentatively, MATN3’s ability to prevent OA-like lesion 
formation in articular cartilage may also be related to its regulatory functions. The complete 
biological mechanism with which this ECM protein acts chondroprotectively remains to be 
elucidated. 
2.3.2 COMP 
Cartilage oligomeric matrix protein (COMP) is another non-collagenous ECM protein found in 
articular cartilage with a function that is not yet completely understood. It is a pentameric 
molecule which consists of five glycoprotein subunits held to one another by disulfide bonds. 
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Each subunit contains an EGF-like domain and a thrombospondin-like domain. Previous 
studies have shown that COMP can stimulate type II collagen fibrillogenesis (Rosenberg et al., 
1998). In cartilage, COMP is found bound to types I, II, and IX collagen molecules. While 
COMP knockout mice exhibit normal chondral and skeletal development, various missense 
mutation in the COMP gene have been shown to cause severe chondrodysplasias such as 
pseudoachondroplasia (PSACH) and MED, which is accompanied by premature OA 
development.  COMP is also used as a marker of OA pathogenesis because its concentration is 
commonly elevated in OA patients (Williams & Spector et al., 2008)     
2.3.3 Lubricin 
Lubricin is a large soluble proteoglycan that is highly expressed by synoviocytes and 
chondrocytes of superficial zone articular cartilage. It is found in the synovial fluid and it 
covers articular surfaces of joints acting as a lubricant that prevents friction induced tissue 
wear and tear during joint transition. Lubricin consists of a central core protein containing 
heavily glycosylated oligosaccharide side chains. The core protein contains two 
somatomedin B-like (SMB) domains, a single a hemopexin-like domain (PEX), and two 
glycosylated mucin-like domains (Rhee et al., 2005). It is coded by the PGR4 gene, which 
when knocked out results in cartilage degradation and synovial cell hyperplasia in mice.  
Mutations in this gene can cause camptodactyly-arthropathy-coxa vara-pericarditis 
syndrome (CACP), which is an autosomal recessive disease that causes synovial hyperplasia 
and joint degredation similar to the phenotype of mice that are completely deficient in this 
protein (Rhee et al., 2005).   
3. Extracellular matrix breakdown during osteoarthritis 
During cartilage turnover, ECM molecules are slowly broken down via proteolysis and 
replaced by newly synthesized ECM proteins secreted from nearby chondrocytes. The 
catabolic and anabolic processes of this turnover are balanced in normal cartilage so that the 
rate of proteolysis and ECM loss matches the rate of ECM synthesis. However, in OA 
cartilage, this balance is often observed to be shifted towards catabolism. Proteases act to 
degrade the ECM network by cleaving excessive amounts collagen and proteoglycans. 
These cleaved fragments are released into the cartilage matrix and some can even trigger 
further tissue catabolism by both known and unknown biological mechanisms. The 
degeneration of the joint cartilage is further enhanced by the lackluster process of tissue 
repair due to disregulated anabolism. During OA, the disregulation of common anabolic 
growth factors native to the articular cartilage (i.e. TGF-ǃ, FGF and IGF) prevents adequate 
protection against the catabolic effects induced by proteases ultimately leading to an 
imbalanced cartilage turnover process that favors degradation.  
3.1 Activation of matrix proteases: MMPs, ADAMTS family 
OA is clinically characterized by its degenerative effect on major articular cartilage ECM 
components such as collagen fibrils and proteoglycans by proteolysis (Takaishi et al., 
2008). This enhancement of articular cartilage ECM catabolism is mediated mostly by the 
matrix metalloproteinase (MMP) family of collagenases and the ADAMTS family of 
aggrecanases, which are often expressed by chondrocytes in response to inflammatory 
cytokines such as IL-1ǃ (Martel-Pelletier et al., 2008; Glasson et al. 2005; Stanton et al., 
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2005). MMPs are neutral zinc-dependent endoproteinases that, when activated, cleave and 
degrade ECM components during normal tissue turnover. The MMP family is divided 
into several categories based on their enzymatic activity: collagenases, gelatinases, 
stromelysins, and membrane-type MMPs (MT-MMPs). MMPs commonly involved in 
cartilage homeostasis are collagenases and gelatinases. Most MMPs are initially secreted 
as inactive pro-MMP proteins (zymogens) which are then activated by proteolytic 
cleavage themselves. Because of their catabolic activity, this family of proteases has 
received much attention in arthritis research. Both mRNA expression and enzymatic 
activity of certain metalloproteinase are increased in cartilage tissue during OA 
pathogenesis including: MMP-1 (Drummond et al., 1999), MMP-2 (Imai et al., 1997; 
Mohtai et al., 1993), MMP-3 (Okada et al., 1992), MMP-7 (Ohta et al., 1998), MMP-8 
(Drummond et al., 1999), MMP-9 (Mohtai et al., 1993), MMP-10 and MMP-13 (Mitchell et 
al., 1996). Table 2 lists OA associated catabolic proteases and the matrix protein targets 
that they cleave. 
 
OA associated proteinase Matrix Substrate 
MMP-1 
Types I,  II,  III,  VII,  VIII,  X collagen 
Aggrecan 
MMP-2 
Types IV, V, VII, X collagen 
Aggrecan, decorin 
MMP-3 
Types II, III, IV, V, IX, X  collagen 
Aggrecan, decorin 
MMP-7 
Types IV, X collagen 
Aggrecan, versican 
MMP-8 
Types I, II, III collagen 
Aggrecan 
MMP-9 
Types IV, V collagen 
Decorin 
MMP-10 
Types III, IV, V collagen 
Aggrecan 
MMP-13 
Types II, III, IV, IX, X collagen 
Aggrecan 
ADAMTS-4 
Aggrecan 
Matrilin-3 
ADAMTS-5 
Aggrecan 
Brevican, matrilin-3 
Table 2. Osteoarthritis (OA) associated MMPs and their cartilage extracellular matrix 
substrates.  
3.1.1 MMP-1 
MMP-1 is classified as a collagenase that shows preference for cleaving type III and type X 
collagens (Martel-Pelletier et al., 2008; Nwomeh et al., 2002) which, while not a major 
component of ECM, is still present in articular cartilage tissue. MMP-1 is stoichiometrically 
inhibited by tissue inhibitor of metalloproteinase (TIMP) 1 and 2.  
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3.1.2 MMP-2 
MMP-2 (gelatinase A) is one of two gelatinases found in human tissues. It further degrades 
a broad range of collagen and proteoglycan species after these substrates have been initially 
cleaved by other protyolitic enzymes (i.e. collagenases and aggrecanases). During OA, most 
of the cartilage tissue damage caused by this metalloproteinase comes from its breakdown 
of aggrecan, decorin, type IV and X collagen. Active MMP-2 is present in superficial and 
transition zones of OA cartilage (Imai et al., 1997).  
3.1.3 MMP-3 
Similarly, MMP-3 is upregulated in early OA but mRNA levels subside during later stages. 
Immunohistochemical studies have previously demonstrated that MMP-3 is expressed 
primarily in the superficial and transition zone in early stage OA cartilage and MMP-3 
staining positively correlates with tissue Mankin scores.  In addition to degrading type IX 
collagen and certain proteoglycans (Martel-Pelletier et al., 2008; Okada et al., 1989), MMP-3 
initiates a cascade that ultimately cleaves and activates pro-MMP-1.  
3.1.4 MMP-7 
Like MMP-2 and MMP-3, MMP-7 is mainly found in the superficial and transition zones of 
OA cartilage (Ohta et al., 1998). This metalloproteinase cleaves type IV and X collagens as 
well as various proteoglycans including aggrecan and versican. Additionally MMP-7 is 
involved in cleavage and activation of MMP-1, MMP-2, MMP-8 and MMP-9 pro-protein 
precursors (Dozier et al., 2006).  
3.1.5 MMP-8 
Unlike other OA associated metalloproteinases, MMP-8 is a collagenase that is produced by 
neutrophils in response to inflammatory cytokines. Although chondrocytes themselves 
produce very little of this catabolic enzyme (Stremme et al., 2003), inflammation of the 
synovium can cause the migration of neutrophils that synthesize and secrete it into and 
around the superficial zone of cartilage contributing to tissue destruction.  MMP-8 cleaves 
type I, II, and III collagen species as well as various proteoglycans including aggrecan.  
3.1.6 MMP-9 
The second gelatinase common to human tissue is MMP-9 (gelatinase B) which prefers 
denatured collagen, mostly type IV and V, as a substrate for its catabolic activity (Okada et 
al., 1992). Its mRNA expression is minimal in normal articular cartilage but it is greatly 
elevated in fibrillated areas of OA cartilage.  
3.1.7 MMP-10 
MMP-10 is a collagenase that degrades collagens types III, IV, V and aggrecan (Nicholson et 
al., 1989; Fosang et al., 1991; Rechardt et al., 2000). It can also cleave and activate pro-MMP-
1, -7, -8 and -9 (Nakamura et al., 1998).  
3.1.8 MMP-13 
Although many members of the MMP family are involved in cartilage ECM catabolism, no 
other MMP is as damaging to cartilage tissue during OA as is the collagenase MMP-13. Type 
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II collagen is the primary structural component of the articular cartilage ECM for which 
MMP-13 shows digestive preference over any other collagen type (Okada et al., 1992; Ohta 
et al., 1998). For this reason, it is the collagenase that causes the most cartilage ECM 
destruction during OA. In addition to type II collagen, it also cleaves type III, IV, IX and X 
collagen species endogenous to cartilage tissue. MMP-13 is normally expressed in many 
different tissues including skin, bone, muscle, and cartilage. Its expression normally 
coincides with type X collagen expression in cartilage undergoing hypertrophic 
differentiation (Kamekura et al., 2005). In normal healthy cartilage, the primary role of 
MMP-13 is to enable hypertrophic zone expansion as it denatures pre-existing type II 
collagen fibrils of the ECM. However, it has been shown that overexpression of MMP-13 in 
articular chondrocytes also induces OA phenotypic changes (Mitchell et al., 1996). Previous 
studies have attempted to use MMP-13 inhibitors such as pyrimidinetrione analogs 
(Drummond et al., 1999) and benzofuran (Blagg et al., 2005) to remedy OA induced cartilage 
damage. However, their responsiveness was found to be dose dependant and often caused 
unwanted musculoskeletal side effects (Wu et al., 2005). 
3.1.9 Aggrecanases 
Aggrecanase-1 (ADAMTS-4) and aggrecanase-2 (ADAMTS-5) are known to be the two most 
active aggrecanases that lead to articular cartilage ECM catabolism during both OA and 
rheumatoid arthritis (RA) (Tortorella et al., 1999;  Abbaszade et al., 1999). ADAMTS-4 and -5 
act on a specific cleavage site (Glu 373/Ala 374) truncating these large proteoglycan chains 
(Kuno et al. 2000; Rodrı´quez-Manzaneque et al., 2002). In addition to their primary activity 
of aggrecan cleavage, they have also been shown to cleave MATN3 tetramers at the alpha-
helical oligomerization domain releasing MATN3 monomers into the extracellular space 
(Ahmad et al., 2009; Tahiri et al., 2008). Interestingly, a meniscal transaction induced OA 
model in mice showed that ADAMTS-5 KO mice sustain less damage to their articular 
cartilage than wild-type mice (Glasson et al., 2005) linking the expression of this aggrecanase 
to diminishing cartilage integrity. 
3.2 Release and function of cleaved matrix proteins 
Proteolytic cleavage of cartilage matrix constituents releases small oligomeric protein 
fragments into the extracellular space where they can mediate further tissue degradation. 
The release of oligomeric fragments produced during cleavage of ECM components such as 
fibronectin, HA, and type II collagen has previously been implicated in the enhancement of 
cartilage catabolism. Increasing concentrations of such fragments in synovial fluid samples 
of patients have been found to positively correlate with increasing grade of OA.  
3.2.1 Fibronectin cleavage fragments 
Fibronectin is a large (450 kDa) adhesive glycoprotein found in many tissues throughout the 
body including articular cartilage. While native fibronectin normally plays a role in cell-to-
cell adhesion and migration, its smaller cleavage fragments (Fn-fs) have different properties 
and function.  Due to enhanced proteolytic cleavage that characteristically occurs during OA 
and RA, elevated levels of Fn-fs (30 – 200 kDa) are commonly found in articular cartilage 
tissue and synovial fluid samples. Interestingly, injecting Fn-fs (but not native full length 
fibronectin) into the knees of rabbits causes up to a 50% depletion of total proteoglycan 
content in articular cartilage (Homandberg et al., 1993). These Fn-fs enhance the release of 
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the catabolic cytokines: IL-1ǂ/ǃ, TNF-, and IL-6, which greatly enhance the release of pro-
MMP-2 and pro-MMP-3, while simultaneously suppressing the expression of aggrecan 
(Bewsey et al., 1996). The exact biological mechanism by which Fn-fs stimulate these 
catabolic effects is currently unknown however, the Fn-fs found in synovial fluid appear to 
bind and penetrate the articular cartilage surface of the superficial zone where they may 
then bind the fibronectin receptors of chondrocytes activating a cascade of events that result 
in the release of the aforementioned inflammatory cytokines (Xie & Homandberg, 1993). 
This is further supported by the finding that competitive inhibition of Fn-fs binding to the 
fibronectin receptor prevents Fn-fs associated catabolic activity (Homandberg & Hui, 1994).  
3.2.2 Hyaluronan cleavage fragments 
As previously discussed, injection of large molecular mass species of HA into the joint space 
of OA patients have been deemed therapeutic due to their pain relieving capabilities. 
However, cleavage of large HA species into smaller HA fragments (HA-fs) by proteolysis or 
oxidation generates oligomers that potentially have different properties than the original 
macromolecule (Soltés et al., 2007). CD44 is the primary cell membrane receptor that binds 
native HA. Adhesion to cells through CD44 allows HA to remain pericellular to 
chondrocytes where HA bound aggrecan aggregates can gather to draw water into the 
cartilage ECM giving the tissue compressive resistance required to withstand forces 
generated during joint loading and movement. However, HA-fs can competitively inhibit 
the interaction between CD44 and native high molecular weight HA species causing 
depletion of this (and other) proteoglycans within the cartilage ECM. Low mass (< 5 kDa) 
HA-fs can also induce MMP-3 and MMP-13 via Nf-kB activation by an unknown biological 
mechanism in explant culture experiments causing damage to cartilage tissue similar to the 
effect of Fn-fs. Additionally, HA-fs, but not native high molecular mass HA, have been 
known to activate iNOS in articular chondrocytes leading to enhanced production of NO 
ultimately causing further joint degredation.  
3.2.3 Collagen cleavage fragments 
During the normal pathophysiology of degenerative joint disease, type II collagen is also 
cleaved and partially degraded to produce smaller protein fragments with novel regulatory 
functions contributing to further tissue catabolism, as is the case with fibronectin and HA. 
Both the C-terminal and N-terminal ends of type II collagen monomers can be cleaved 
through proteolysis producing fragments termed CT and NT peptides, respectively. Such 
fragments have been shown to penetrate cartilage tissue and greatly enhance the mRNA 
expression of MMP-2, 3, 9, and 13 (Fichter et al., 2006) through MAPK p38 and NFκB 
signaling causing ECM breakdown and proteoglycan depletion (Guo et al., 2009).  Similar to 
the way that HA-fs competitively inhibit HA interaction with CD44, it is surmised that type 
II collagen fragments can also bind chondrocyte cell membrane integrins preventing these 
receptors from interacting with type II collagen fibrils, thereby disrupting collagen network 
integrity. Annexin V is another chondrocyte cell membrane receptor that commonly 
interacts with native type II collagen. This interaction is vital for matrix vesicle mediated 
cartilage calcification. Like native type II collagen, the NT peptide can also regulate 
calcification by binding and activating this receptor. In high concentration, the NT peptide 
may potentially be responsible for pathological mineralization of the cartilage tissue as 
commonly seen in OA.  
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4. Extracellular matrix repair during osteoarthritis 
In addition to ECM degradation due to the presence of reactive proteases, as well as their 
catabolic by-products (such as cleaved matrix protein fragments), OA is also characterized 
by a disregulation of important structural proteins as well as several important growth 
factors and their respective antagonists. This altered anabolism is most likely a 
compensatory reaction by chondrocytes attempting to repair OA induced tissue damage. 
However, the enhanced expression of some anabolic factors can trigger significant changes 
to cartilage homeostasis exacerbating the situation.  
4.1 Altered expression of structural proteins 
While proteolytic processing of collagens is a common characteristic of OA, some of these 
structural proteins exhibit increased expression and synthesis during disease pathogenesis. 
Type II, and VI collagens are both highly expressed in OA cartilage. The increase in these native 
collagen species also provide substrates for proteolysis which generates collagen fragments that 
have catabolic properties that ultimately results in MMP and NO release followed by 
proteoglycan depletion, as discussed previously. It is understandable how such events can 
mediate further tissue degradation during OA.  Additionally, the expression and spatial 
distribution of type X collagen also changes in the OA joint.  While typically type X collagen 
expression is only localized to the calcified zone, which lies right above the subchondral bone, 
this marker is also expressed by middle zone cartilage during OA pathogenesis.  The 
appearance of type X collagen is often indicative of calcification, which seems to corroborate the 
increased tissue mineralization characteristic of later stages of this disease.    
Although aggrecan expression is initially increased during early stage OA, during later 
stages of OA, its expression is downregulated in cartilage. Thus aggrecan depletion from 
cartilage tissue is not simply a result by ECM breakdown but it is also due to altered gene 
regulation. While the biological mechanism responsible for such alterations in gene 
regulation is not completely understood, it is at least partly due to cytokines and growth 
factors that are produced by chondrocytes, synoviocytes, and tissue localized immune cells 
during OA pathogenesis.          
4.2 Altered expression of growth factors 
The disregulation of potent growth factors during OA can significantly change tissue 
morphology. 
4.2.1 BMPs & TGF-β 
While members of the bone morphogenic protein (BMP) family are present in low amounts 
in normal articular cartilage, their expression is altered during OA. Normally, BMP-2, 4, 6, 7, 
9, and 13 are expressed in articular cartilage. These growth factors stimulate chondrocytes to 
synthesize ECM constituents such as aggrecan and type II collagen to undergo 
chondrogenic differentiation. They play a role in cartilage repair and help to maintain joint 
integrity. Some members of the family such as BMP-7 can even inhibit inflammatory 
cytokine induced MMP synthesis in chondrocytes and synoviocytes. This family of growth 
factors also has endogenous inhibitors known as BMP antagonists. BMP antagonists are a 
group of proteins that function by directly binding BMPs as to prohibit them from 
interacting with their cognate receptors. This effectively prevents BMP signaling.  During 
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OA, only BMP-2 is reported to be upregulated. However, BMP antagonists are also highly 
expressed in this disease. These antagonists alter normal cartilage homeostasis by inhibiting 
ECM anabolism mediated by all BMPs and significantly hindering cartilage tissue repair.  
The expression and protein synthesis of the transforming growth factor beta (TGF-ǃ) family are 
also altered during OA pathogenesis. Normal cartilage contains small amounts of these growth 
factors as they promote chondrocyte proliferation and chondrogenic differentiation.  Similar to 
BMPs, they stimulate synthesis of ECM constituent proteins type II collagen and aggrecan. 
Additionally, TGF-ǃ inhibits the expression and synthesis of MMP-1 and MMP-9. However, the 
exact function of TGF-ǃ in the joint is still somewhat controversial due to its strong stimulation 
of MMP-13 and ADAMTS-4 expression in chondrocytes. OA cartilage displays a greater 
abundance of TGF-ǃ than seen in normal non-diseased cartilage. This is consistent with the 
increase of both MMP-13 and ADAMTS-4 observed during disease progression.  Inhibition of 
TGF-ǃ has also been shown effective in preventing osteophyte formation in OA cartilage 
explants suggesting that this growth factor may play a role in inhibiting chondrocyte 
hypertrophy and premature ossification characteristic of OA (Scharstuhl et al., 2002). 
4.2.2 IGFs, FGFs & HGF 
Insulin-like growth factors (IGFs) and fibroblast growth factors (FGFs) are also two important 
proteins that are disregulated during OA. There are two types IGFs: IGF-1 and IGF-2. Both 
IGFs are present at higher levels in OA cartilage than normal. IGFs regulate homeostatic 
processes in many tissue types. In articular cartilage it promotes cell division, growth, and 
proteoglycan synthesis.  A family of insulin-like growth factors binding proteins (IGFBPs) can 
modulate IGF activity by direct interaction.  Out of the seven currently known IGFBPs (IGFBP-
1 to 7), IGFBP-3 is the most common protein to modulate IGF activity. It has been shown that 
IGFBP-3 can inhibit the activity of both IGF-1 and IGF-2 in a dose dependant manner (Devi et 
al., 2001). In articular cartilage, IGFBP-3 has been found to increase in abundance with age. 
During OA pathogenesis, IGFBP-3 levels are increased even further potentially hindering the 
process of tissue repair. Like IGFs, FGFs are also upregulated during OA. This family of 
proteins includes 22 currently identified members. In cartilage biology, the most studied 
members are FGF-2, FGF-9, and FGF-18 due to their strong stimulation of matrix synthesis and 
tissue repair. However, the role of these growth factors during OA progression remains to be 
elucidated. Hepatocyte growth factor (HGF) is another potent multifunctional mitogenic 
protein that is disregulated in OA cartilage. Deep zone cartilage tissue normally contains two 
different truncated HGF isoforms (NK1 and NK2) (Guévremont et al., 2003). Although full 
length HGF is not produced by chondrocytes, osteoblasts from the subchondral bone produce 
HGF which may be processed in the nearby tissue generating these truncated peptides which 
diffuse into the calcified and deep zones of cartilage. MMP-13 expression is enhanced by 
chondrocytes and synoviocytes that come into contact with HGF. Its increasing abundance in 
OA cartilage can potentially enhance collagen fibril catabolism. Interestingly, HGF is also 
known for its ability to induce angiogenesis. It is unclear whether this function directly 
exacerbates the inflammation commonly characteristic of degenerative joint diseases. 
5. Effect of major OA associated cytokines and chemokines on cartilage ECM 
Unlike RA, OA is not traditionally classified an inflammatory arthropathy.  It is unclear if 
the inflammation is intrinsic to osteoarthritis or a manifestation of associated crystal (e.g., 
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calcium pyrophosphate or hydroxyapatite) arthritis complicating the osteoarthritis. It is 
characterized by mild yet chronic inflammation that indirectly plays a significant role in 
disease progression and tissue destruction. Pro-inflammatory cytokine and chemokine 
production by mononuclear cells, cells of the synovial membrane, and articular 
chondrocytes can disrupt normal cartilage homeostasis favoring proteoglycan depletion and 
tissue destruction. The two main pro-inflammatory cytokines noted for their destructive 
effects during OA are IL-1ǃ and TNF-ǂ.  
5.1 IL-1β 
IL-1ǃ is expressed and released mainly by synoviocytes and mononuclear cells during joint 
inflammation, but studies have shown that articular chondrocytes of OA cartilage too 
upregulate its expression and synthesis. IL-1ǃ exerts several significant catabolic and anti-
anabolic effects that make it the most disease causative cytokine in OA.  It induces 
expression of the collagenases, especially MMP-1, MMP-3, MMP-9 and MMP-13, which are 
believed to contribute significantly to the enhancement of articular cartilage catabolism that 
occurs during OA (Martel-Pelletier et al., 2008). The IL-1ǃ pathway ultimately activates 
nuclear factor-κB (NFκB), which is necessary for the transcription of many genes relevant to 
OA and joint inflammation including MMPs (Park et al., 2004). It has been shown in murine 
articular cartilage explants that suppressing MMP production via IκB kinase inhibitiors is 
sufficient to reduce the degredation of both type II collagen and aggrecan (Pattoli et al., 
2005).     
The ability of IL-1ǃ to downregulate the expression of type II collagen and aggrecan, the two 
main structural components of the articular cartilage ECM, further illustrates how this 
pathway can potentially hinder ECM repair in OA pathogenesis. It has been previously 
demonstrated that IL-1ǃ induces a greater than twofold downregulation of both type II 
collagen and aggrecan expression in human chondrocytes (Toegal et al., 2008; Goldring et al., 
1988). The production of type II collagen and aggrecan are important to the process of 
chondrogenesis during which mesenchymal stem cells of the chondrocyte lineage secrete 
the ECM protein components necessary to constitute articular cartilage. Even though 
chondrogenesis occurs primarily during development in humans, it can also be induced as a 
result of damage sustained to existing cartilage (as in the case of OA) (van Beuningen et al., 
2000). IL-1ǃ can inhibit chondrogenesis (Murakami et at., 2000) by downregulating the 
transcription factor SOX9 (Wehrli et al., 2003), which is a master regulator of the 
chondrogenesis pathway. Similarly, IL-1ǃ downregulates the expression of certain TIMPs 
that normally bind and inhibit active MMPs (Martel-Pelletier et al., 2008). It is also known 
that the IL-1 receptor (IL-1RI) expression is higher in OA cartilage than in normal cartilage 
(Jacques et al., 2006) indicating the possibility that the IL-1ǃ pathway is more active in OA 
chondrocytes. IL-1RI KO mice are resistant to the early development of OA (Jacques et al., 
2006). All evidence point to IL-1ǃ stimulation as a potential cause of articular cartilage ECM 
breakdown during OA. This is why it may be possible to regulate IL-1ǃ activity, perhaps 
through endogenous pathway inhibition, to slow down OA development/progression. 
5.1.1 IL-1RI and IL-1RA 
The IL-1ǃ pathway has several endogenous inhibitors (Martel-Pelletier et al., 2008; Arend et 
al., 2000).  Normal signal transduction of this pathway is initiated upon ligand binding to 
the IL-1 receptor (IL-1RI). The ligand binding event enables IL-1RI to associate with another 
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cell membrane bound protein known as the interleukin-1 receptor accessory protein (IL-
1RAcP), which is necessary for pathway activation (Wesche et al., 1997). The association of 
these two membrane bound proteins allows for cross phosphorylation to occur in their 
transmembrane signaling domains initiating the signaling cascade that eventually leads to 
transcription of the proteases and cytokines described previously. Interleukin-1 receptor II 
(IL-1RII) is a cell membrane bound protein which competes with IL-1RI for IL-1 ligand 
binding (Gabay et al., 2010). IL-1RII is an IL-1RI protein mimic that does not contain a 
transmembrane signaling domain therefore it will not initiate signal transduction of the 
pathway and it is classified as an IL-1ǃ pathway inhibitor. Two other endogenous inhibitors 
of this pathway are known as soluble interleukin-1 receptor II (sIL-1RII) and soluble 
interleukin-1 receptor accessory protein (sIL-1RAcP) (Gabay et al., 2010).  These proteins 
mimic IL-1RI and IL-1RAcP respectively. sIL-1RII competes with IL-1RI to bind IL-1ǃ, 
similarly sIL-1RAcP competes with IL-1RAcP to bind the IL-1RI.  
The fifth, and arguable the most effective, inhibitor of this pathway is the IL-1RA. This protein 
is an IL-1ǂ/ǃ protein mimic and binds IL-1RI with a much higher affinity than does either IL-
1ǂ or IL-1ǃ.  IL-1RA bound IL-1RI cannot associate with IL-1RAcP and therefore is unable to 
initiate signal transduction of the IL-1ǃ pathway. The IL-1RA gene can be alternatively spliced 
to form different isoforms. Currently four isoforms are known to exist in humans and two in 
mice. In humans, there are three intracellular isoforms of IL-RA (icIL-RA1, icIL-RA2, icIL-RA3) 
and one cell secreted isoform (sIL-1RA). The intracellular isoforms tend to be cell associated 
and stays in contact with the cell membrane of the cell from which it was produced. The 
secreted form of IL-1RA, however, can move into the extracellular space and proceed to inhibit 
the IL-1ǃ signal transduction of cells that are further away. Several of these isoforms can be 
easily distinguished form one another due to their varying size: icIL-RA1/ icIL-RA2 (18-kDa), 
icIL-RA3 (16-kDa), and sIL-1RA (17-kDa) (Gabay et al., 2010). 
IL-1RA is produced by many cell types including articular chondrocytes. It has been 
established that chondrocyte produced/secreted IL-1RA protein helps sustain articular 
cartilage integrity during both RA and OA induced inflammation. The later was 
demonstrated when chondrocytes taken from OA cartilage, which was transduced with  
IL-1RA, protected against IL-1-induced cartilage degradation in organ culture experiments 
(Baragi et al., 1995). Further support for the idea that IL-1RA is chondroprotective comes 
from IL-1RA knockout mice of multiple genetic backgrounds, which have been shown to 
develop early arthritis compared to wild-type mice of the same background (Arend et al., 
2000). IL-RA knockout mice bred in both BALB/cA and MFIx129 backgrounds developed 
severe inflammatory arthritis. Additionally, IL-1ǃ protein levels where elevated as high as 
three fold in these IL-1RA knock-out mice of both backgrounds while detectable levels of B-
cells and T-cells remained constant between IL-1RA knock-out and wild-type mice (Nicklin 
et al., 2000). 
In 1999, in vivo IL-1RA gene transfer experiments done in rabbits also demonstrated its 
potential to reduce OA severity. In these experiments, OA was artificially induced in the 
animals via meniscectomy after which local IL-1RA gene therapy by intra-articular plasmid 
injection was performed at 24 hour intervals 4 weeks post surgery. The animals were 
sacrificed exactly 4 weeks after the first injection and the joint synoviums were dissected 
and stained for IL-1RA. The level of IL-1RA present in the synoviums of these rabbits 
positively correlated with a reduction in articular cartilage lesions that resulted from OA 
indicating that IL-1RA was chondroprotective (Fernandes et al., 1999). A more recent study 
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in 2005 looked at the levels of several potential chondrodestructive (IL-1ǂ, IL-1ǃ, TNF-ǂ, 
etc.) as well as chondroprotective cytokines, one of which was sIL-1RA, in 31 patients who 
are at a higher risk of developing OA in one of their knees due to chronic anterior cruciate 
ligament (ACL) deficiency. This study found concentrations of IL-1ǃ and TNF-ǂ to be 
significantly higher in the ACL deficient vs. normal knees while the concentration of sIL-
1RA decreased with increasing grades of articular chondral damage (Marks et al., 2005). 
Finally, a 2008 randomized double-blinded cohort study done in 167 patients with knee OA 
looked at the symptomatic effect of chromium sulfate induced autologous IL-1RA 
production and found a significant reduction of OA induced pain in the treated patients 
based on Knee injury and Osteoarthritis Outcome Score (KOOS) and Knee Society Clinical 
Rating System .    
It is important to note that the chondroprotective effects of IL-1RA during OA are only 
observable when the protein is consistently present in the joint synovium of the arthritic 
joint. This explains why short-lived drugs such as AnikinRA (Cohen, 2004), which only last 
4 hours post-intraarticular injection into human patients (as determined by serum analysis) 
have limited efficacy in treating OA progression (Chevalier et al., 2009). This is also most 
likely the underlying reason behind the success of longer lasting treatment options such as 
gene therapy and other methods aimed at increasing autologous IL-1RA production within 
the synovium of the OA joint.  
5.2 TNF-α 
Second only to IL-1ǃ, TNF-ǂ is a potent pro-inflammatory cytokine responsible for initiating 
much joint destruction during OA and other such joint degenerative diseases. TNF-ǂ is 
currently looked on as a potential target for late stage OA therapy as its appearance in the 
joint is a telltale sign of advanced severity of the disease. In late stage OA, both TNF-ǂ and 
its p55 receptor undergoes increased expression by articular chondrocytes and synoviocytes 
enhancing TNF-ǂ pathway signaling. This leads to increased production of NO, ECM 
degrading enzymes, especially the highly catabolic collagenases MMP-3 and MMP-13, and 
other inflammatory cytokines like IL-1 and IL-6, which overall off-balances tissue 
homeostasis favoring ECM destruction. TNF-ǂ also enhances the synthesis and release of 
the prostaglandin PGE2, which inhibits chondrocyte differentiation and maturation while 
simultaneously promoting MMP production and IL-6 expression. Additionally, circulating 
mononuclear cells that are localized to areas of inflammation that have undergone OA 
induced tissue injury also release TNF-ǂ worsening joint inflammation and ultimately 
further favoring catabolism.  Although commercially available TNF-ǂ inhibitors are most 
efficacious for relieving of RA associated joint inflammation, it has been demonstrated that 
certain inhibitors, such as infliximab and etanercept, can suppress NO production in human 
cartilage (Vuolteenaho et al., 2002) making them potentially effective for treating OA. 
Despite these findings, only a handful of clinical studies have delved into testing the efficacy 
of this approach to OA treatment.  
5.3 SDF-1 
Recently, SDF-1 has received attention in arthritis research. Patients suffering from OA and 
RA display an increase of this chemokine in their synovial fluid.  Although no evidence 
suggests that chondrocytes produce SDF-1, superficial and deep zone chondrocytes do 
however express the SDF-1 receptor (CXCR4) (Kanbe et al., 2002). Both synovial fibroblasts 
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and osteoblasts from the subchondral bone produce SDF-1 and so it is also found in the 
deep zone of cartilage tissue. During OA pathogenesis, macrophages and lymphoid cells 
that have been localized to the inflamed synovium and/or joint cartilage will produce this 
chemokine. Since SDF-1 is known for its strong chemotactic abilities attracting lymphocytes 
to the site of joint inflammation, it has been implicated in enhancing cartilage tissue 
catabolism. In addition to its chemotactic ability, SDF-1 also stimulates the production of 
MMP-3 and MMP-13 by interacting with the CXCR4 receptors of articular chondrocytes 
(Kanbe et al., 2002; Chiu et al., 2007) contributing to collagen and proteoglycan cleavage. 
6. Conclusion and future prospects in ECM biology and OA treatment 
There are no FDA approved drugs specific for the treatment of OA. Currently, the most 
effective interventions merely alleviate OA symptoms. The three main interventions 
available are: (1) Supplements that attempt to enhance the body’s endogenous cartilage 
regenerative capabilities, (2) Drugs that attempt to reduce OA associated pain, and (3) 
Surgical interventions such as total joint replacement, which is currently the most effective 
form of relieving the pain and inflammation occuring during the more severe later stages of 
this degenerative joint disease. Today, total joint replacement is a commonly performed 
routine surgery. It offers significant and permanent pain relief that other alternative 
therapies cannot provide, but it remains to be the last resort for late stage OA sufferers.    
The use of anti-cytokine therapy to prevent cartilage tissue destruction has recently received 
attention in OA research. As previously discussed, OA induced ECM destruction most 
closely associates with induction of the IL-1ǃ and TNF-ǂ pathways. These major 
inflammatory cytokines stimulate mononuclear cells, synovial fibroblasts, and articular 
chondrocytes to release IL-6, NO, and chemokines that enhance joint damage. They 
additionally disregulate the release of anabolic growth factors and tissue destructive 
proteolytic enzymes from chondrocytes causing major alteration in the process of cartilage 
homeostasis. Numerous in vitro and in vivo studies conducted in animal models show that 
using IL-1Ra protein to inhibit IL-1ǃ pathway activation has promise for preventing OA 
induced ECM degradation and inflammation.  However, in human studies, the efficacy of 
IL-1 pathway inhibition for the purpose of OA therapy has been somewhat less successful. 
A paper published in 2009 reported the short-term efficacy of treating OA patients with 
recombinant IL-1Ra protein (Anakinra), which is a anti-inflammatory drug initially 
approved by the FDA for the treatment of RA. In this randomized double-blinded study, 
160 knee OA sufferers were given 50 to 150 mg of Anakinra via intra-articular injection and 
their status was monitored for 4 weeks. During this time, knee joint pain was graded using 
the WOMAC pain index. Although there was no observable difference in cartilage 
destruction between the 150 mg Anakinra and placebo injected groups, Anakinra did prove 
to reduce OA associated knee joint pain on the fourth day after treatment. However, given 
the short half-life of this recombinant protein (approximately 5 hours), it did not have a 
significant beneficial effect after the fourth day (Chevalier et al., 2009). Similarly, inhibition 
of IL-1ǃ and IL-1 receptor expression using a synthetic anti-inflammatory analgesic 
molecule named Diacerein has proved to have similar pain relieving effects with the 
additional benefit of preventing ECM catabolism to some degree. This drug also seems to 
have longer lasting therapeutic effects than Anakinra due to its relative stability (Pelletier et 
al., 2000).  
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As previously discussed, the intra-articular (or joint) injection of disease modifying ECM 
proteins such as lubricin and HA have been somewhat effective in reducing inflammation 
and tissue destruction. Similar use of various growth factors to repair OA induced ECM 
damage may be another promising avenue that warrants further investigation. Recent 
studies using “Preparations rich in growth factors” (PRGF), commonly consisting of platelet 
rich plasma (PRP),  have demonstrated the efficacy of combining anabolic and anti-catabolic 
proteins to deliver a dual beneficial effect that reduces proteolytic ECM breakdown and 
promotes tissue repair in OA joints. Several studies conducted in the past decade have 
demonstrated that PRDF treatment reduces joint pain up to 5 weeks post injection while also 
showing signs that it may enhance regenerative capabilities of cartilage tissue. However, 
some of anabolic proteins used in these growth factor cocktails (i.e. TGF-ǃ, IGF) are known 
to already be increased during OA pathogenesis. More studies need to be conducted in 
order to understand the mode by which such therapies are chondroprotective. Currently the 
use of PRP for the treatment of knee OA is in Phase 2 of clinical trials.  
Localized intra-articular gene therapy is a very exciting and novel approach for treating 
degenerative joint diseases such as OA and RA. It provides a controlled method to sustain 
production of potentially therapeutic gene products that cannot be matched by more 
transient methods such as simple intra-articular injection. Sites of localized gene transfer 
include the synovium (most common target in past studies) as well as articular cartilage 
tissue itself. Thus far, gene candidates used for this approach include those that can 
potentially enhance ECM synthesis and repair and/or prevent ECM breakdown. IL-1Ra is 
an example of a chondroprotective gene that has been successfully utilized for gene transfer 
experiments in several animal models. These studies clearly show positive outcomes 
correlating with its expression within the joint including reduced inflammation and 
decreased tissue destruction (Calich et al., 2010). IGF-1 is another gene candidate that has 
been introduced into the knee joints of rabbits via adenovirus mediated gene transfer. These 
animals experienced enhanced ECM synthesis by the articular cartilage in their knee joints 
under both normal and inflamed conditions (Mi et al., 2000). The use of gene therapy for the 
treatment of OA has presented much promise; however, due to issues involving the 
practicality of its use, we are still a long time away from utilizing its full potential.     
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